title: Modern and conventional prognostic markers of chronic lymphocytic leukaemia in the everyday haematological practice.
abstract: OBJECTIVE
  The impact of modern prognostic markers on clinical course of chronic lymphocytic leukaemia (CLL) in everyday practice has been not yet well defined, especially in large series of patients. Therefore, the goal of this study was to assess the influence of conventional as well as modern prognostic factors on overall survival (OS) and time to therapy (TTT) of patients with CLL.
  
  
  METHODS
  We retrospectively analysed data of all patients consecutively entered into the databases of five large academic centres in the Czech Republic. The total of 1300 patients was included in the analysis.
  
  
  CONCLUSIONS
  Through the use of uniparametric analysis, it was determined that gender, clinical stage Rai II-IV, unmutated IgVH status, deletion 17p (for both 5% and 20% cut-off), deletion 11q, ZAP-70 positivity and high expression of CD38 had significant negative influence on OS. TTT was significantly influenced by gender, Rai stage, IgVH status, deletion 11q, deletion 17p, deletion 13q and CD38 expression. Multiparametric analysis revealed that OS was significantly influenced by gender, age, IgVH status and deletion 17p. If only patients who died of CLL were included, gender, age, Rai stage, IgVH status and deletion 17p had significant influence on OS. Based on our results, the examination of biological prognostic markers can give an insight into the possible disease evolution in daily clinical practice. Biological prognostic markers are, however, not ready (maybe except deletion 17p in younger patients) to be used for guidance of therapy at least outside of clinical trials.
authors.affiliation: Department of Internal Medicine-Hematology/Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. mdoubek@fnbrno.cz
authors.forename: Michael
authors.initials: M
authors.lastname: Doubek
authors.forename: Jiří
authors.initials: J
authors.lastname: Mayer
authors.forename: Petra
authors.initials: P
authors.lastname: Obrtlíková
authors.forename: Lukáš
authors.initials: L
authors.lastname: Smolej
authors.forename: Eduard
authors.initials: E
authors.lastname: Cmunt
authors.forename: Jiří
authors.initials: J
authors.lastname: Schwarz
authors.forename: Martin
authors.initials: M
authors.lastname: Brejcha
authors.forename: Petr
authors.initials: P
authors.lastname: Kozmon
authors.forename: Sárka
authors.initials: S
authors.lastname: Pospíšilová
authors.forename: Yvona
authors.initials: Y
authors.lastname: Brychtová
authors.forename: Zdeněk
authors.initials: Z
authors.lastname: Pospíšil
authors.forename: Marek
authors.initials: M
authors.lastname: Trněný
mesh_terms: D051997:ADP-ribosyl Cyclase 1 / Q000097:blood; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood; D002872:Chromosome Deletion; D002880:Chromosomes, Human, Pair 11 / Q000235:genetics; D002886:Chromosomes, Human, Pair 17 / Q000235:genetics; D018450:Disease Progression; D005260:Female; D050438:Genes, Immunoglobulin Heavy Chain; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000209:etiology* / Q000235:genetics / Q000276:immunology / Q000473:pathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000209:etiology; D008297:Male; D008562:Membrane Glycoproteins / Q000097:blood; D008875:Middle Aged; D009154:Mutation; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D051746:ZAP-70 Protein-Tyrosine Kinase / Q000097:blood
chemical_list: D014408:Biomarkers, Tumor; D008562:Membrane Glycoproteins; D051746:ZAP-70 Protein-Tyrosine Kinase; C497261:ZAP70 protein, human; C498154:CD38 protein, human; D051997:ADP-ribosyl Cyclase 1